<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240313203700&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240313203700&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 14 Mar 2024 00:37:02 +0000</lastbuilddate>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The art of deciphering and communicating cardiovascular risk: getting it right</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38478708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 13:ehae103. doi: 10.1093/eurheartj/ehae103. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38478708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38478708</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae103>10.1093/eurheartj/ehae103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38478708</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Safi U Khan</dc:creator>
<dc:creator>Sadeer A-Kindi</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The art of deciphering and communicating cardiovascular risk: getting it right</dc:title>
<dc:identifier>pmid:38478708</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae103</dc:identifier>
</item>
<item>
<title>What's VAT All About-The Clue Is in the Genetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0092. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38477927</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0092>10.1001/jamacardio.2024.0092</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477927</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Sharlene M Day</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>What's VAT All About-The Clue Is in the Genetics</dc:title>
<dc:identifier>pmid:38477927</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0092</dc:identifier>
</item>
<item>
<title>Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477913/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Findings of this randomized clinical trial indicate that QCA and IVUS guidance during PCI showed similar rates of target lesion failure at 12 months. However, due to the lower-than-expected rates of target lesion failure in this trial, the findings should be interpreted with caution.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0059. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Although intravascular ultrasonography (IVUS) guidance promotes favorable outcomes after percutaneous coronary intervention (PCI), many catheterization laboratories worldwide lack access.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate whether systematic implementation of quantitative coronary angiography (QCA) to assist angiography-guided PCI could be an alternative strategy to IVUS guidance during stent implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, noninferiority clinical trial enrolled adults (aged ≥18 years) with chronic or acute coronary syndrome and angiographically confirmed native coronary artery stenosis requiring PCI. Patients were enrolled in 6 cardiac centers in Korea from February 23, 2017, to August 23, 2021, and follow-up occurred through August 25, 2022. All principal analyses were performed according to the intention-to-treat principle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: After successful guidewire crossing of the first target lesion, patients were randomized in a 1:1 ratio to receive either QCA- or IVUS-guided PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was target lesion failure at 12 months, defined as a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. The trial was designed assuming an event rate of 8%, with the upper limit of the 1-sided 97.5% CI of the absolute difference in 12-month target lesion failure (QCA-guided PCI minus IVUS-guided PCI) to be less than 3.5 percentage points for noninferiority.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The trial included 1528 patients who underwent PCI with QCA guidance (763; mean [SD] age, 64.1 [9.9] years; 574 males [75.2%]) or IVUS guidance (765; mean [SD] age, 64.6 [9.5] years; 622 males [81.3%]). The post-PCI mean (SD) minimum lumen diameter was similar between the QCA- and IVUS-guided PCI groups (2.57 [0.55] vs 2.60 [0.58] mm, P = .26). Target lesion failure at 12 months occurred in 29 of 763 patients (3.81%) in the QCA-guided PCI group and 29 of 765 patients (3.80%) in the IVUS-guided PCI group (absolute risk difference, 0.01 percentage points [95% CI, -1.91 to 1.93 percentage points]; hazard ratio, 1.00 [95% CI, 0.60-1.68]; P = .99). There was no difference in the rates of stent edge dissection (1.2% vs 0.7%, P = .25), coronary perforation (0.2% vs 0.4%, P = .41), or stent thrombosis (0.53% vs 0.66%, P = .74) between the QCA- and IVUS-guided PCI groups. The risk of the primary end point was consistent regardless of subgroup, with no significant interaction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Findings of this randomized clinical trial indicate that QCA and IVUS guidance during PCI showed similar rates of target lesion failure at 12 months. However, due to the lower-than-expected rates of target lesion failure in this trial, the findings should be interpreted with caution.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02978456.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477913/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38477913</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0059>10.1001/jamacardio.2024.0059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477913</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Pil Hyung Lee</dc:creator>
<dc:creator>Soon Jun Hong</dc:creator>
<dc:creator>Hyun-Sook Kim</dc:creator>
<dc:creator>Young Won Yoon</dc:creator>
<dc:creator>Jong-Young Lee</dc:creator>
<dc:creator>Seung-Jin Oh</dc:creator>
<dc:creator>Ji Sung Lee</dc:creator>
<dc:creator>Soo-Jin Kang</dc:creator>
<dc:creator>Young-Hak Kim</dc:creator>
<dc:creator>Seong-Wook Park</dc:creator>
<dc:creator>Seung-Whan Lee</dc:creator>
<dc:creator>Cheol Whan Lee</dc:creator>
<dc:creator>GUIDE-DES Trial Research Group</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38477913</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0059</dc:identifier>
</item>
<item>
<title>Moving Beyond Conventional Guesstimation to Guide PCI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0071. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38477911</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0071>10.1001/jamacardio.2024.0071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477911</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Moving Beyond Conventional Guesstimation to Guide PCI</dc:title>
<dc:identifier>pmid:38477911</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0071</dc:identifier>
</item>
<item>
<title>Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that epicardial and pericardial adiposity was associated with incident cardiovascular diseases, but this may largely reflect a metabolically unhealthy adiposity phenotype similar to abdominal visceral adiposity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0080. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Epicardial and pericardial adipose tissue (EPAT) has been associated with cardiovascular diseases such as atrial fibrillation or flutter (AF) and coronary artery disease (CAD), but studies have been limited in sample size or drawn from selected populations. It has been suggested that the association between EPAT and cardiovascular disease could be mediated by local or paracrine effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association of EPAT with prevalent and incident cardiovascular disease and to elucidate the genetic basis of EPAT in a large population cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A deep learning model was trained to quantify EPAT area from 4-chamber magnetic resonance images using semantic segmentation. Cross-sectional and prospective cardiovascular disease associations were evaluated, controlling for sex and age. Prospective associations were additionally controlled for abdominal visceral adipose tissue (VAT) volumes. A genome-wide association study was performed, and a polygenic score (PGS) for EPAT was examined in independent FinnGen cohort study participants. Data analyses were conducted from March 2022 to December 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: The primary exposures were magnetic resonance imaging-derived continuous measurements of epicardial and pericardial adipose tissue area and visceral adipose tissue volume.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Prevalent and incident CAD, AF, heart failure (HF), stroke, and type 2 diabetes (T2D).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After exclusions, this study included 44 475 participants (mean [SD] age, 64.1 [7.7] years; 22 972 female [51.7%]) from the UK Biobank. Cross-sectional and prospective cardiovascular disease associations were evaluated for a mean (SD) of 3.2 (1.5) years of follow-up. Prospective associations were additionally controlled for abdominal VAT volumes for 38 527 participants. A PGS for EPAT was examined in 453 733 independent FinnGen cohort study participants. EPAT was positively associated with male sex (β = +0.78 SD in EPAT; P &lt; 3 × 10-324), age (Pearson r = 0.15; P = 9.3 × 10-229), body mass index (Pearson r = 0.47; P &lt; 3 × 10-324), and VAT (Pearson r = 0.72; P &lt; 3 × 10-324). EPAT was more elevated in prevalent HF (β = +0.46 SD units) and T2D (β = +0.56) than in CAD (β = +0.23) or AF (β = +0.18). EPAT was associated with incident HF (hazard ratio [HR], 1.29 per +1 SD in EPAT; 95% CI, 1.17-1.43), T2D (HR, 1.63; 95% CI, 1.51-1.76), and CAD (HR, 1.19; 95% CI, 1.11-1.28). However, the associations were no longer significant when controlling for VAT. Seven genetic loci were identified for EPAT, implicating transcriptional regulators of adipocyte morphology and brown adipogenesis (EBF1, EBF2, and CEBPA) and regulators of visceral adiposity (WARS2 and TRIB2). The EPAT PGS was associated with T2D (odds ratio [OR], 1.06; 95% CI, 1.05-1.07; P =3.6 × 10-44), HF (OR, 1.05; 95% CI, 1.04-1.06; P =4.8 × 10-15), CAD (OR, 1.04; 95% CI, 1.03-1.05; P =1.4 × 10-17), AF (OR, 1.04; 95% CI, 1.03-1.06; P =7.6 × 10-12), and stroke in FinnGen (OR, 1.02; 95% CI, 1.01-1.03; P =3.5 × 10-3) per 1 SD in PGS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that epicardial and pericardial adiposity was associated with incident cardiovascular diseases, but this may largely reflect a metabolically unhealthy adiposity phenotype similar to abdominal visceral adiposity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38477908</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0080>10.1001/jamacardio.2024.0080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477908</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Cody R Hou</dc:creator>
<dc:creator>Samuel F Friedman</dc:creator>
<dc:creator>Carolina Roselli</dc:creator>
<dc:creator>Victor Nauffal</dc:creator>
<dc:creator>Satoshi Koyama</dc:creator>
<dc:creator>Juha Karjalainen</dc:creator>
<dc:creator>Mahnaz Maddah</dc:creator>
<dc:creator>Aarno Palotie</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>James P Pirruccello</dc:creator>
<dc:creator>FinnGen</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity</dc:title>
<dc:identifier>pmid:38477908</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0080</dc:identifier>
</item>
<item>
<title>A Female in Her 50s With Caseating Mitral Annulus Calcification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 13. doi: 10.1001/jamacardio.2024.0074. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38477890</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0074>10.1001/jamacardio.2024.0074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477890</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Iva Minga</dc:creator>
<dc:creator>Vinesh Appadurai</dc:creator>
<dc:creator>Vera Rigolin</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>A Female in Her 50s With Caseating Mitral Annulus Calcification</dc:title>
<dc:identifier>pmid:38477890</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0074</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38477842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 1;9(3):202. doi: 10.1001/jamacardio.2023.3651.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38477842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38477842</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3651>10.1001/jamacardio.2023.3651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38477842</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38477842</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3651</dc:identifier>
</item>
<item>
<title>Tackling inflammation in atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38472372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 12. doi: 10.1038/s41569-024-01007-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38472372/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38472372</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01007-z>10.1038/s41569-024-01007-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38472372</guid>
<pubDate>Wed, 13 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Mohsen Shoaran</dc:creator>
<dc:creator>Pasquale Maffia</dc:creator>
<dc:date>2024-03-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Tackling inflammation in atherosclerosis</dc:title>
<dc:identifier>pmid:38472372</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01007-z</dc:identifier>
</item>
<item>
<title>Intravenous iron, only for those in need</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 13:ehae093. doi: 10.1093/eurheartj/ehae093. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38471820</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae093>10.1093/eurheartj/ehae093</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471820</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Niels Grote Beverborg</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron, only for those in need</dc:title>
<dc:identifier>pmid:38471820</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae093</dc:identifier>
</item>
<item>
<title>Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471643/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: With further experience, SESAME may benefit patients requiring septal reduction therapy for obstructive hypertrophic cardiomyopathy, with LVOT obstruction after heart valve replacement, and/or to prepare for transcatheter valve implantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 16:S0735-1097(24)00280-8. doi: 10.1016/j.jacc.2024.02.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a source of morbidity in hypertrophic cardiomyopathy (HCM) and a life-threatening complication of transcatheter mitral (TMVR) and aortic valve replacement (TAVR). Available surgical and transcatheter approaches are limited by high surgical risk, unsuitable septal perforators, and heart block requiring permanent pacemakers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We report the initial experience of a novel transcatheter electrosurgical procedure developed to mimic surgical myotomy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used SEptal Scoring Along Midline Endocardium (SESAME) to treat patients, on a compassionate basis, with symptomatic LVOT obstruction or to create space to facilitate TMVR or TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this single-center retrospective study between 2021-2023, 76 patients underwent SESAME. Eleven (14%) had classic HCM, and the remainder underwent SESAME to facilitate TMVR or TAVR. All had technically successful SESAME myocardial laceration. Measures to predict post-TMVR LVOT significantly improved (neo-LVOT 42(7,117)to 170(95,265)mm<sup>2</sup>,p&lt;0.001; skirt-neo-LVOT 169(153,193) to 214(180,262)mm<sup>2</sup>,p&lt;0.001). Among patients with HCM, SESAME significantly decreased invasive LVOT gradients (resting: 54[40,70] to 29[12,36]mmHg,p=0.023; provoked 146[100,180] to 85[40,120]mmHg,p=0.076). Seventy-four (97.4%) survived the procedure. Five suffered 3/76(3.9%) iatrogenic ventricular septal defects that did not require repair, and 3/76(3.9%) ventricular free wall perforations. Neither occurred in patients treated for HCM. Permanent pacemakers were required in 4/76(5.3%), including two after concomitant TAVR. Lacerations were stable and did not propagate after SESAME (remaining septum: 5.9±3.3mm to 6.3±3.4mm,p=0.6).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: With further experience, SESAME may benefit patients requiring septal reduction therapy for obstructive hypertrophic cardiomyopathy, with LVOT obstruction after heart valve replacement, and/or to prepare for transcatheter valve implantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471643/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38471643</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.007>10.1016/j.jacc.2024.02.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471643</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Adam B Greenbaum</dc:creator>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Patrick T Gleason</dc:creator>
<dc:creator>Jaffar M Khan</dc:creator>
<dc:creator>Christopher G Bruce</dc:creator>
<dc:creator>Rim N Halaby</dc:creator>
<dc:creator>Toby Rogers</dc:creator>
<dc:creator>George S Hanzel</dc:creator>
<dc:creator>Joe X Xie</dc:creator>
<dc:creator>Isida Byku</dc:creator>
<dc:creator>Robert A Guyton</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>John C Lisko</dc:creator>
<dc:creator>Nikoloz Shekiladze</dc:creator>
<dc:creator>Errol K Inci</dc:creator>
<dc:creator>Elizabeth A Grier</dc:creator>
<dc:creator>Gaetano Paone</dc:creator>
<dc:creator>James M McCabe</dc:creator>
<dc:creator>Robert J Lederman</dc:creator>
<dc:creator>Vasilis C Babaliaros</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction</dc:title>
<dc:identifier>pmid:38471643</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.007</dc:identifier>
</item>
<item>
<title>Metabolic trade-offs constrain the cell size ratio in a nitrogen-fixing symbiosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>Biological dinitrogen (N(2)) fixation is a key metabolic process exclusively performed by prokaryotes, some of which are symbiotic with eukaryotes. Species of the marine haptophyte algae Braarudosphaera bigelowii harbor the N(2)-fixing endosymbiotic cyanobacteria UCYN-A, which might be evolving organelle-like characteristics. We found that the size ratio between UCYN-A and their hosts is strikingly conserved across sublineages/species, which is consistent with the size relationships of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 6:S0092-8674(24)00182-X. doi: 10.1016/j.cell.2024.02.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Biological dinitrogen (N<sub>2</sub>) fixation is a key metabolic process exclusively performed by prokaryotes, some of which are symbiotic with eukaryotes. Species of the marine haptophyte algae Braarudosphaera bigelowii harbor the N<sub>2</sub>-fixing endosymbiotic cyanobacteria UCYN-A, which might be evolving organelle-like characteristics. We found that the size ratio between UCYN-A and their hosts is strikingly conserved across sublineages/species, which is consistent with the size relationships of organelles in this symbiosis and other species. Metabolic modeling showed that this size relationship maximizes the coordinated growth rate based on trade-offs between resource acquisition and exchange. Our findings show that the size relationships of N<sub>2</sub>-fixing endosymbionts and organelles in unicellular eukaryotes are constrained by predictable metabolic underpinnings and that UCYN-A is, in many regards, functioning like a hypothetical N<sub>2</sub>-fixing organelle (or nitroplast).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38471501</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.016>10.1016/j.cell.2024.02.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471501</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Francisco M Cornejo-Castillo</dc:creator>
<dc:creator>Keisuke Inomura</dc:creator>
<dc:creator>Jonathan P Zehr</dc:creator>
<dc:creator>Michael J Follows</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Metabolic trade-offs constrain the cell size ratio in a nitrogen-fixing symbiosis</dc:title>
<dc:identifier>pmid:38471501</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.016</dc:identifier>
</item>
<item>
<title>The underappreciated diversity of bile acid modifications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38471500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>The repertoire of modifications to bile acids and related steroidal lipids by host and microbial metabolism remains incompletely characterized. To address this knowledge gap, we created a reusable resource of tandem mass spectrometry (MS/MS) spectra by filtering 1.2 billion publicly available MS/MS spectra for bile-acid-selective ion patterns. Thousands of modifications are distributed throughout animal and human bodies as well as microbial cultures. We employed this MS/MS library to identify...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 6:S0092-8674(24)00185-5. doi: 10.1016/j.cell.2024.02.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The repertoire of modifications to bile acids and related steroidal lipids by host and microbial metabolism remains incompletely characterized. To address this knowledge gap, we created a reusable resource of tandem mass spectrometry (MS/MS) spectra by filtering 1.2 billion publicly available MS/MS spectra for bile-acid-selective ion patterns. Thousands of modifications are distributed throughout animal and human bodies as well as microbial cultures. We employed this MS/MS library to identify polyamine bile amidates, prevalent in carnivores. They are present in humans, and their levels alter with a diet change from a Mediterranean to a typical American diet. This work highlights the existence of many more bile acid modifications than previously recognized and the value of leveraging public large-scale untargeted metabolomics data to discover metabolites. The availability of a modification-centric bile acid MS/MS library will inform future studies investigating bile acid roles in health and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38471500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38471500</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.019>10.1016/j.cell.2024.02.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38471500</guid>
<pubDate>Tue, 12 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ipsita Mohanty</dc:creator>
<dc:creator>Helena Mannochio-Russo</dc:creator>
<dc:creator>Joshua V Schweer</dc:creator>
<dc:creator>Yasin El Abiead</dc:creator>
<dc:creator>Wout Bittremieux</dc:creator>
<dc:creator>Shipei Xing</dc:creator>
<dc:creator>Robin Schmid</dc:creator>
<dc:creator>Simone Zuffa</dc:creator>
<dc:creator>Felipe Vasquez</dc:creator>
<dc:creator>Valentina B Muti</dc:creator>
<dc:creator>Jasmine Zemlin</dc:creator>
<dc:creator>Omar E Tovar-Herrera</dc:creator>
<dc:creator>Sarah Moraïs</dc:creator>
<dc:creator>Dhimant Desai</dc:creator>
<dc:creator>Shantu Amin</dc:creator>
<dc:creator>Imhoi Koo</dc:creator>
<dc:creator>Christoph W Turck</dc:creator>
<dc:creator>Itzhak Mizrahi</dc:creator>
<dc:creator>Penny M Kris-Etherton</dc:creator>
<dc:creator>Kristina S Petersen</dc:creator>
<dc:creator>Jennifer A Fleming</dc:creator>
<dc:creator>Tao Huan</dc:creator>
<dc:creator>Andrew D Patterson</dc:creator>
<dc:creator>Dionicio Siegel</dc:creator>
<dc:creator>Lee R Hagey</dc:creator>
<dc:creator>Mingxun Wang</dc:creator>
<dc:creator>Allegra T Aron</dc:creator>
<dc:creator>Pieter C Dorrestein</dc:creator>
<dc:date>2024-03-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The underappreciated diversity of bile acid modifications</dc:title>
<dc:identifier>pmid:38471500</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.019</dc:identifier>
</item>
<item>
<title>Correction to: Development and Validation of the American Heart Association's PREVENT Equations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e956. doi: 10.1161/CIR.0000000000001230. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466792</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001230>10.1161/CIR.0000000000001230</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466792</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Development and Validation of the American Heart Association's PREVENT Equations</dc:title>
<dc:identifier>pmid:38466792</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001230</dc:identifier>
</item>
<item>
<title>Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466791/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):839-842. doi: 10.1161/CIRCULATIONAHA.123.068089. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466791/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466791</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068089>10.1161/CIRCULATIONAHA.123.068089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466791</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure</dc:title>
<dc:identifier>pmid:38466791</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068089</dc:identifier>
</item>
<item>
<title>Dual (Ischemic and Nonischemic) Cardiomyopathy: A Wolf in Sheep's Clothing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466790/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):822-824. doi: 10.1161/CIRCULATIONAHA.123.068090. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466790/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466790</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068090>10.1161/CIRCULATIONAHA.123.068090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466790</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Gladys Juncà</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dual (Ischemic and Nonischemic) Cardiomyopathy: A Wolf in Sheep's Clothing</dc:title>
<dc:identifier>pmid:38466790</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068090</dc:identifier>
</item>
<item>
<title>Letter by Heuts et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466789/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):892-893. doi: 10.1161/CIRCULATIONAHA.123.066934. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466789/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466789</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066934>10.1161/CIRCULATIONAHA.123.066934</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466789</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Samuel Heuts</dc:creator>
<dc:creator>Patrick O Myers</dc:creator>
<dc:creator>Matthias Siepe</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Heuts et al Regarding Article, "Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial"</dc:title>
<dc:identifier>pmid:38466789</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066934</dc:identifier>
</item>
<item>
<title>Antiarrhythmic Drug Therapy: Where Do We Go From Here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):801-803. doi: 10.1161/CIRCULATIONAHA.123.066989. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466788</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066989>10.1161/CIRCULATIONAHA.123.066989</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466788</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter R Kowey</dc:creator>
<dc:creator>Gerald V Naccarelli</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antiarrhythmic Drug Therapy: Where Do We Go From Here?</dc:title>
<dc:identifier>pmid:38466788</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066989</dc:identifier>
</item>
<item>
<title>Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):804-806. doi: 10.1161/CIRCULATIONAHA.123.065887. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466787</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065887>10.1161/CIRCULATIONAHA.123.065887</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466787</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jonathan G Peter</dc:creator>
<dc:creator>Ntobeko A B Ntusi</dc:creator>
<dc:creator>Mpiko Ntsekhe</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Are Recommendations That Favor Other Agents Over Angiotensin-Converting Enzyme Inhibitors in Africans With Hypertension Justified?</dc:title>
<dc:identifier>pmid:38466787</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065887</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18987</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e959. doi: 10.1161/CIR.0000000000001228. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466786</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001228>10.1161/CIR.0000000000001228</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466786</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18987</dc:title>
<dc:identifier>pmid:38466786</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001228</dc:identifier>
</item>
<item>
<title>End-Stage Heart Failure in Cardiac Sarcoidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):885-887. doi: 10.1161/CIRCULATIONAHA.123.066962. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466785</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066962>10.1161/CIRCULATIONAHA.123.066962</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466785</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Diana Velikanova</dc:creator>
<dc:creator>Pauli Pöyhönen</dc:creator>
<dc:creator>Jukka Lehtonen</dc:creator>
<dc:creator>Piia Simonen</dc:creator>
<dc:creator>Valtteri Uusitalo</dc:creator>
<dc:creator>Tapani Vihinen</dc:creator>
<dc:creator>Kari Kaikkonen</dc:creator>
<dc:creator>Petri Haataja</dc:creator>
<dc:creator>Tuomas Kerola</dc:creator>
<dc:creator>Tuomas T Rissanen</dc:creator>
<dc:creator>Ville Vepsäläinen</dc:creator>
<dc:creator>Aleksi Alatalo</dc:creator>
<dc:creator>Päivi Pietilä-Effati</dc:creator>
<dc:creator>Markku Kupari</dc:creator>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>End-Stage Heart Failure in Cardiac Sarcoidosis</dc:title>
<dc:identifier>pmid:38466785</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066962</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18918</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38466784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240313203700&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 12;149(11):e958. doi: 10.1161/CIR.0000000000001229. Epub 2024 Mar 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38466784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240313203700&v=2.18.0.post9+e462414">38466784</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001229>10.1161/CIR.0000000000001229</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38466784</guid>
<pubDate>Mon, 11 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18918</dc:title>
<dc:identifier>pmid:38466784</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001229</dc:identifier>
</item>





























</channel>
</rss>